ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Yuexiang Wang
Matched on ORCID iD 0000-0003-3229-5467; OpenAlex author ID A5101676318. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 24
2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper
Papers 6
- Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s44321-024-00060-y↗
- Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
- Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
- Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Last author DOI 10.1002/adbi.201900236↗
- Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Last author DOI 10.1093/carcin/bgz086↗
- Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7397↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Liwei Wang · 3 shared papers, 2022–2024 · strength 0.38
- Paper Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. DOI 10.1038/s44321-024-00060-y↗
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Jiujie Cui · 3 shared papers, 2022–2024 · strength 0.38
- Paper Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. DOI 10.1038/s44321-024-00060-y↗
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Zhang Li · 2 shared papers, 2020–2021 · strength 0.32
- Simin Wang · 2 shared papers, 2020–2024 · strength 0.26
- Xiaoxiao Liu · 1 shared paper, 2021 · strength 0.22
- Feng Jiao · 2 shared papers, 2022 · strength 0.22
- Yingbin Liu · 2 shared papers, 2022 · strength 0.22
- Xiaofei Zhang · 2 shared papers, 2022 · strength 0.22
- Tiebo Mao · 2 shared papers, 2022 · strength 0.22
- Jiong Hu · 2 shared papers, 2022 · strength 0.22
- Yongwei Sun · 2 shared papers, 2022 · strength 0.22
- Jiayu Yao · 2 shared papers, 2022 · strength 0.22
- Deliang Fu · 2 shared papers, 2022 · strength 0.22
- Xiaoqi Li · 1 shared paper, 2024 · strength 0.16
- Yu Wang · 1 shared paper, 2022 · strength 0.11
- Qiang Liu · 1 shared paper, 2022 · strength 0.11
- Shumin Li · 1 shared paper, 2022 · strength 0.11
- Weiyu Ge · 1 shared paper, 2022 · strength 0.11
- Yu Wang · 1 shared paper, 2022 · strength 0.11
- Ke Li · 1 shared paper, 2020 · strength 0.10
- Chenghao Shao · 1 shared paper, 2020 · strength 0.10
- Ziran Wei · 1 shared paper, 2016 · strength 0.06
- Qingping Cai · 1 shared paper, 2016 · strength 0.06
- Dejun Yang · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.